Fujian Haixi Pharmaceuticals (2637) Announces New Senior Management Appointment

Bulletin Express03-01

Fujian Haixi Pharmaceuticals Co., Ltd. (Stock Code: 2637) announced the appointment of Dr. Zhang Mingqiang as President of Research & Development and Global Affairs, effective March 1, 2026. Dr. Zhang, aged 65, brings extensive experience from pharmaceutical and biotechnology companies worldwide.

Dr. Zhang previously led the medicinal chemistry section at Organon research laboratories in Glasgow from 1997 to 2001 and co-founded several biotechnology ventures before joining multinational pharmaceutical firms. Between 2003 and 2009, Dr. Zhang served as senior vice president of research & development at Biotica Technology Ltd in Cambridge, focusing on synthetic biology. He later held roles at F. Hoffmann-La Roche’s R&D Centre in China and returned to Merck Sharp & Dohme as corporate vice president and head of Asia Pacific Research & Development from 2011 to 2012. Since 2012, he had been corporate vice president of R&D and head of the Asia Research & Development Center at Amgen Inc.

According to the announcement, Dr. Zhang’s background is expected to support business development activities worldwide and guide the research and development of novel drugs. The board expressed confidence that his extensive experience and in-depth knowledge will help the company achieve new milestones and strengthen its strategic direction moving forward.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1145194990?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-01 18:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1145194990","market":"hk","top_or_hot":-1,"title":"Fujian Haixi Pharmaceuticals (2637) Announces New Senior Management Appointment","media":"Bulletin Express","content":"<p>Fujian Haixi Pharmaceuticals Co., Ltd. (Stock Code: 2637) announced the appointment of Dr. Zhang Mingqiang as President of Research & Development and Global Affairs, effective March 1, 2026. Dr. Zhang, aged 65, brings extensive experience from pharmaceutical and biotechnology companies worldwide.</p>\n<p>Dr. Zhang previously led the medicinal chemistry section at Organon research laboratories in Glasgow from 1997 to 2001 and co-founded several biotechnology ventures before joining multinational pharmaceutical firms. Between 2003 and 2009, Dr. Zhang served as senior vice president of research & development at Biotica Technology Ltd in Cambridge, focusing on synthetic biology. He later held roles at F. Hoffmann-La Roche’s R&D Centre in China and returned to Merck Sharp & Dohme as corporate vice president and head of Asia Pacific Research & Development from 2011 to 2012. Since 2012, he had been corporate vice president of R&D and head of the Asia Research & Development Center at Amgen Inc.</p>\n<p>According to the announcement, Dr. Zhang’s background is expected to support business development activities worldwide and guide the research and development of novel drugs. The board expressed confidence that his extensive experience and in-depth knowledge will help the company achieve new milestones and strengthen its strategic direction moving forward.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Fujian Haixi Pharmaceuticals (2637) Announces New Senior Management Appointment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFujian Haixi Pharmaceuticals (2637) Announces New Senior Management Appointment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-01 18:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Fujian Haixi Pharmaceuticals Co., Ltd. (Stock Code: 2637) announced the appointment of Dr. Zhang Mingqiang as President of Research & Development and Global Affairs, effective March 1, 2026. Dr. Zhang, aged 65, brings extensive experience from pharmaceutical and biotechnology companies worldwide.</p>\n<p>Dr. Zhang previously led the medicinal chemistry section at Organon research laboratories in Glasgow from 1997 to 2001 and co-founded several biotechnology ventures before joining multinational pharmaceutical firms. Between 2003 and 2009, Dr. Zhang served as senior vice president of research & development at Biotica Technology Ltd in Cambridge, focusing on synthetic biology. He later held roles at F. Hoffmann-La Roche’s R&D Centre in China and returned to Merck Sharp & Dohme as corporate vice president and head of Asia Pacific Research & Development from 2011 to 2012. Since 2012, he had been corporate vice president of R&D and head of the Asia Research & Development Center at Amgen Inc.</p>\n<p>According to the announcement, Dr. Zhang’s background is expected to support business development activities worldwide and guide the research and development of novel drugs. The board expressed confidence that his extensive experience and in-depth knowledge will help the company achieve new milestones and strengthen its strategic direction moving forward.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02637","symbol_name":"海西新药","start_time":0,"source_url":"","article_id":"1145194990","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1145194990","pubTimestamp":1772360748,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Fujian Haixi Pharmaceuticals Co., Ltd. (Stock Code: 2637) announced the appointment of Dr. Zhang Mingqiang as President of Research & Development and Global Affairs, effective March 1, 2026. Dr....","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02637":"海西新药"},"translate_title":"福建海西药业(2637)公布新高级管理层任命","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02637":1},"content_text":"Fujian Haixi Pharmaceuticals Co., Ltd. (Stock Code: 2637) announced the appointment of Dr. Zhang Mingqiang as President of Research & Development and Global Affairs, effective March 1, 2026. Dr. Zhang, aged 65, brings extensive experience from pharmaceutical and biotechnology companies worldwide.\nDr. Zhang previously led the medicinal chemistry section at Organon research laboratories in Glasgow from 1997 to 2001 and co-founded several biotechnology ventures before joining multinational pharmaceutical firms. Between 2003 and 2009, Dr. Zhang served as senior vice president of research & development at Biotica Technology Ltd in Cambridge, focusing on synthetic biology. He later held roles at F. Hoffmann-La Roche’s R&D Centre in China and returned to Merck Sharp & Dohme as corporate vice president and head of Asia Pacific Research & Development from 2011 to 2012. Since 2012, he had been corporate vice president of R&D and head of the Asia Research & Development Center at Amgen Inc.\nAccording to the announcement, Dr. Zhang’s background is expected to support business development activities worldwide and guide the research and development of novel drugs. The board expressed confidence that his extensive experience and in-depth knowledge will help the company achieve new milestones and strengthen its strategic direction moving forward.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"executive,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1145194990","isCrawlerRequest":true}